NO20083547L - Novel spiro[imidazolidine-4,3'-indole]-2,2",5' (1'H)-triones for treatment of conditions associated with vanilloid receptor 1 - Google Patents

Novel spiro[imidazolidine-4,3'-indole]-2,2",5' (1'H)-triones for treatment of conditions associated with vanilloid receptor 1

Info

Publication number
NO20083547L
NO20083547L NO20083547A NO20083547A NO20083547L NO 20083547 L NO20083547 L NO 20083547L NO 20083547 A NO20083547 A NO 20083547A NO 20083547 A NO20083547 A NO 20083547A NO 20083547 L NO20083547 L NO 20083547L
Authority
NO
Norway
Prior art keywords
triones
imidazolidine
indole
treatment
conditions associated
Prior art date
Application number
NO20083547A
Other languages
English (en)
Norwegian (no)
Inventor
Miroslaw Tomaszewski
Carmen Leung
Simon Woo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083547(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20083547L publication Critical patent/NO20083547L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
NO20083547A 2006-02-07 2008-08-14 Novel spiro[imidazolidine-4,3'-indole]-2,2",5' (1'H)-triones for treatment of conditions associated with vanilloid receptor 1 NO20083547L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77111906P 2006-02-07 2006-02-07
PCT/SE2007/000107 WO2007091947A2 (en) 2006-02-07 2007-02-06 Novel spiro[imidazolidine-4,3'-indole]-2,2',5(1'h)-triones for treatment of conditions associated with vanilloid receptor 1

Publications (1)

Publication Number Publication Date
NO20083547L true NO20083547L (no) 2008-11-05

Family

ID=38345567

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083547A NO20083547L (no) 2006-02-07 2008-08-14 Novel spiro[imidazolidine-4,3'-indole]-2,2",5' (1'H)-triones for treatment of conditions associated with vanilloid receptor 1

Country Status (21)

Country Link
US (2) US20070185179A1 (https=)
EP (1) EP2013215A4 (https=)
JP (1) JP2009526043A (https=)
KR (1) KR20080094906A (https=)
CN (1) CN101415711A (https=)
AR (1) AR059265A1 (https=)
AU (1) AU2007212786B2 (https=)
BR (1) BRPI0707423A2 (https=)
CA (1) CA2641632A1 (https=)
CL (1) CL2009000523A1 (https=)
IL (1) IL192890A0 (https=)
NO (1) NO20083547L (https=)
NZ (1) NZ571070A (https=)
RU (1) RU2421457C2 (https=)
SA (1) SA07280027B1 (https=)
SG (1) SG169387A1 (https=)
TW (1) TW200801011A (https=)
UA (1) UA93226C2 (https=)
UY (1) UY30132A1 (https=)
WO (1) WO2007091947A2 (https=)
ZA (1) ZA200806407B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781521A4 (en) 2011-10-19 2015-03-04 Kowa Co NEW SPIROINDOLIN COMPOUND AND MEDICAL AGENT THEREFOR
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CN108409746B (zh) * 2018-05-15 2021-08-24 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU532110B2 (en) 1979-11-13 1983-09-15 Ici Ltd. Spiro(imidazolidine-4,3:-indoline)-2,2:5-trione derivatives
ZA806623B (en) * 1979-11-13 1981-12-30 Ici Ltd Substituted indoline-2-one derivatives
IE52879B1 (en) 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
GB8331194D0 (en) 1982-12-20 1983-12-29 Ici Plc Chemical process
US4611062A (en) * 1984-03-26 1986-09-09 Imperial Chemical Industries Plc Process for resolving certain spiro compounds
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
HUP0203548A3 (en) * 1999-07-21 2003-04-28 Astrazeneca Ab New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
US7248802B2 (en) 2002-11-27 2007-07-24 Nokia Corporation Distribution of a synchronization signal in an optical communication system
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
US7585878B2 (en) 2003-06-12 2009-09-08 Astellas Pharma Inc. Benzamide derivative or salt thereof
GB0326633D0 (en) * 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
US7879866B2 (en) 2004-07-19 2011-02-01 Dorte Xenia Gram Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders
WO2007091948A2 (en) * 2006-02-07 2007-08-16 Astrazeneca Ab Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1

Also Published As

Publication number Publication date
SA07280027B1 (ar) 2010-11-22
AU2007212786A1 (en) 2007-08-16
AU2007212786A8 (en) 2010-05-06
IL192890A0 (en) 2009-02-11
NZ571070A (en) 2011-07-29
WO2007091947A8 (en) 2008-08-07
AU2007212786B2 (en) 2011-06-02
RU2008131905A (ru) 2010-03-20
EP2013215A2 (en) 2009-01-14
US7868181B2 (en) 2011-01-11
ZA200806407B (en) 2009-04-29
CN101415711A (zh) 2009-04-22
EP2013215A4 (en) 2010-09-08
CL2009000523A1 (es) 2009-07-17
BRPI0707423A2 (pt) 2011-05-03
RU2421457C2 (ru) 2011-06-20
WO2007091947A3 (en) 2007-10-04
SG169387A1 (en) 2011-03-30
KR20080094906A (ko) 2008-10-27
JP2009526043A (ja) 2009-07-16
TW200801011A (en) 2008-01-01
UY30132A1 (es) 2009-07-17
CA2641632A1 (en) 2007-08-16
US20090137650A1 (en) 2009-05-28
AR059265A1 (es) 2008-03-19
WO2007091947A2 (en) 2007-08-16
UA93226C2 (en) 2011-01-25
US20070185179A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
RU2704112C2 (ru) Ингибиторы рецептора фактора роста фибробластов
CN111936471B (zh) 非稠合噻吩衍生物及其用途
CO5700742A2 (es) Moduladores del receptor de quimioquina ccr5
EA039885B1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
CN108276352A (zh) 一种具有杀线虫活性的含氮杂环化合物及其制法和用途
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
WO2008094909A2 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
NO20075406L (no) Pyrimidindionerivater som prokineticin-2-reseprorantagonister
ES2374017T3 (es) Agentes terapéuticos útiles para el tratamiento del dolor.
MX2011013294A (es) Antagonistas de la trayectoria de hedgehog y aplicaciones terapeuticas de los mismos.
CN115991706A (zh) Pim激酶抑制剂
NO20083547L (no) Novel spiro[imidazolidine-4,3'-indole]-2,2",5' (1'H)-triones for treatment of conditions associated with vanilloid receptor 1
EP4736860A2 (en) Polycyclic compounds for inhibiting rna helicase dhx33 and use thereof
WO2008155669A3 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
WO2009115486A1 (en) Triazole amide derivatives for use in therapy
MA32947B1 (fr) Piperidines substitues par aroylamino et heteroaroylamino comme inhibiteurs de glyt-1
CN113166119A (zh) 取代芳基化合物及其制备方法和用途
TW202012401A (zh) 縮環內醯胺衍生物
ATE468118T1 (de) Bis-1,2,3,4-tetrahydroisochinolinderivate und ihre verwendung als pharmazeutika
GB0501964D0 (en) Chemical compounds
JP2022547200A (ja) 三環系構造を有する芳香複素環式化合物、およびその調製方法と適用
CN110054622A (zh) 噁二唑类衍生物、其制备方法及其在医药上的应用
ATE388945T1 (de) Benzoxazolderivate und deren verwendung als adenosinrezeptorliganden
CA2605144C (en) Substituted cyclic urea derivatives and the use thereof as vanilloid receptor 1 modulators

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application